WO2004064716A3 - Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders - Google Patents

Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders Download PDF

Info

Publication number
WO2004064716A3
WO2004064716A3 PCT/GB2004/000242 GB2004000242W WO2004064716A3 WO 2004064716 A3 WO2004064716 A3 WO 2004064716A3 GB 2004000242 W GB2004000242 W GB 2004000242W WO 2004064716 A3 WO2004064716 A3 WO 2004064716A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
inflammatory disorders
treating inflammatory
docosapentaenoic
eicosapentaenoic
Prior art date
Application number
PCT/GB2004/000242
Other languages
French (fr)
Other versions
WO2004064716A2 (en
Inventor
David Frederick Horrobin
Original Assignee
Pabay Invest Ltd
Horrobin David F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pabay Invest Ltd, Horrobin David F filed Critical Pabay Invest Ltd
Publication of WO2004064716A2 publication Critical patent/WO2004064716A2/en
Publication of WO2004064716A3 publication Critical patent/WO2004064716A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of eicosapentaenoic acid or derivative in the treatment or prevention of psoriasis or other inflammatory disorder.
PCT/GB2004/000242 2003-01-24 2004-01-22 Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders WO2004064716A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301701.9 2003-01-24
GBGB0301701.9A GB0301701D0 (en) 2003-01-24 2003-01-24 Psoriasis and Eicosapentaenoic acid

Publications (2)

Publication Number Publication Date
WO2004064716A2 WO2004064716A2 (en) 2004-08-05
WO2004064716A3 true WO2004064716A3 (en) 2004-10-28

Family

ID=9951772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000242 WO2004064716A2 (en) 2003-01-24 2004-01-22 Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders

Country Status (2)

Country Link
GB (1) GB0301701D0 (en)
WO (1) WO2004064716A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021555A1 (en) * 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
NZ573719A (en) * 2006-07-05 2011-08-26 Photonz Corp Ltd Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
ES2561482T3 (en) 2007-02-15 2016-02-26 Centre De Recherche Sur Les Biotechnologies Marine Monoglycerides of polyunsaturated fatty acid, derivatives, and their uses
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
WO2008119146A2 (en) * 2007-03-29 2008-10-09 Dair, Bicudo Piai Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US8298554B2 (en) 2009-04-29 2012-10-30 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
CN104042617A (en) 2009-04-29 2014-09-17 阿马里纳药物爱尔兰有限公司 Pharmaceutical Compositions Comprising Epa And A Cardiovascular Agent And Methods Of Using The Same
PT2443246T (en) 2009-06-15 2018-03-14 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9861605B2 (en) * 2011-10-24 2018-01-09 Stable Solutions Llc Enriched injectable emulsion containing selected fatty acid triglycerides
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (en) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Compositions and methods for reducing high sensitivity levels (hs-CRP) in a subject
WO2013150384A1 (en) * 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
NZ743706A (en) 2012-06-29 2019-08-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CA2889238A1 (en) * 2012-10-23 2014-05-01 Deakin University Method for reducing triglycerides
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019210424A1 (en) 2018-05-03 2019-11-07 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
MX2021002553A (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244921A (en) * 1990-03-21 1993-09-14 Martek Corporation Eicosapentaenoic acids and methods for their production
JPH08109128A (en) * 1994-08-19 1996-04-30 Toshiyuki Watanabe Preparation for treating allergic dermatopathy for external use
WO1999053935A1 (en) * 1998-04-16 1999-10-28 Ida Development A/S Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga
WO2000044361A2 (en) * 1999-01-27 2000-08-03 Laxdale Limited Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
WO2002089787A1 (en) * 2001-05-09 2002-11-14 Laxdale Limited Potentiation of therapeutic effects of fatty acids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244921A (en) * 1990-03-21 1993-09-14 Martek Corporation Eicosapentaenoic acids and methods for their production
JPH08109128A (en) * 1994-08-19 1996-04-30 Toshiyuki Watanabe Preparation for treating allergic dermatopathy for external use
WO1999053935A1 (en) * 1998-04-16 1999-10-28 Ida Development A/S Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga
WO2000044361A2 (en) * 1999-01-27 2000-08-03 Laxdale Limited Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
WO2002089787A1 (en) * 2001-05-09 2002-11-14 Laxdale Limited Potentiation of therapeutic effects of fatty acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199627, Derwent World Patents Index; Class B05, AN 1996-263783, XP002277346 *

Also Published As

Publication number Publication date
GB0301701D0 (en) 2003-02-26
WO2004064716A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004064716A3 (en) Eicosapentaenoic acid and docosapentaenoic acid for treating inflammatory disorders
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2004106486A3 (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
HK1091813A1 (en) 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
NO20053678D0 (en) Combination therapy for the treatment of immune inflammatory disorders
IL172170A0 (en) Propionic acid derivatives useful in the treatment of lipid disorders
EP3330252A3 (en) Isoprenyl compounds and methods thereof
WO2006055871A3 (en) Treatment for multiple sclerosis
IL181706A0 (en) The treatment of inflammatory disorders and pain
EP1489915A4 (en) Treatment and prevention of inflammatory disorders
EP1711197A4 (en) Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
GB2460976B (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
WO2007084542A3 (en) Treatment of inflammatory disorders with triazole compounds
AU2003259246A8 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
WO2005016272A3 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
WO2004096848A8 (en) Novel composition and methods for the treatment of immune disorders
WO2005037208A3 (en) Nitrone compounds prodrugs and pharmaceutical compositions of the same to treat human disorders
WO2001037832A3 (en) Combination of riluzole and gabapentin and use thereof as medicine
AU2003225430A1 (en) Composition and method for the treatment or prevention of il-1 mediated disorders
AUPS255402A0 (en) Agents and methods for the treatment of disorders associated with oxidative stress

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase